Financial Contrast: Valneva (NASDAQ:VALN) and Absci (NASDAQ:ABSI)

Absci (NASDAQ:ABSI) and Valneva (NASDAQ:VALN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, valuation and earnings.

Profitability

This table compares Absci and Valneva’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Absci	-7,756.38%	-61.71%	-54.52%
Valneva	-110.33%	-153.20%	-39.50%

Valuation & Earnings

This table compares Absci and Valneva”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Absci	$1.56 million	1,046.61	-$115.18 million	($0.80)	-11.90
Valneva	$142.94 million	4.34	-$130.33 million	($2.11)	-3.10

Absci has higher earnings, but lower revenue than Valneva. Absci is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Absci has a beta of 2.42, indicating that its share price is 142% more volatile than the S&P 500. Comparatively, Valneva has a beta of 1.67, indicating that its share price is 67% more volatile than the S&P 500.

Insider & Institutional Ownership

52.0% of Absci shares are owned by institutional investors. Comparatively, 11.4% of Valneva shares are owned by institutional investors. 10.5% of Absci shares are owned by insiders. Comparatively, 14.9% of Valneva shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Absci and Valneva, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Absci	1	0	9	0	2.80
Valneva	2	0	1	0	1.67

Absci presently has a consensus target price of $13.71, suggesting a potential upside of 44.06%. Valneva has a consensus target price of $9.30, suggesting a potential upside of 42.20%. Given Absci’s stronger consensus rating and higher probable upside, equities analysts clearly believe Absci is more favorable than Valneva.

Summary

Absci beats Valneva on 9 of the 14 factors compared between the two stocks.

About Absci

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.